Preclinical & Translational Project Manager

Benjamin obtained his PhD from the Grenoble Institute of Neurosciences where he studied the role of stress neuromediators in Intestinal Bowel disease flares and colon cancer progression.
Afterwards, he integrated Patrick Mehlen’s laboratory as a postdoctoral fellow, investigating the function of Netrin-1 in cancer stem cells.
Benjamin joined NETRIS Pharma in 2014 to coordinate the preclinical pharmacology studies of the NP137, the anti-Netrin-1 drug candidate. With the opening of NP137 clinical trials, he is now also in charge of ancillary studies focusing on Netrin-1 detection and biomarkers research.